col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world


75 Results       Page 1

 [1] 
Wiley: Clinical Pharmacology & Therapeutics
  original article Date Title Authors   All Authors
1 [GO] 2023―Mar―25 Successes and Opportunities during the Pandemic: Reflections and Revelations from a Vaccine Development Perspective Penny M. Heaton, Kavitha Palaniappan, Anne-Claire Stona, Silke Vogel, John C. W. Lim
2 [GO] 2023―Feb―15 Mycophenolic acid exposure determines antibody formation following SARS-CoV -2 vaccination in kidney transplant recipients: a nested cohort study Soufian Meziyerh, Pim Bouwmans, Teun van Gelder, Danny van der Helm, Lianne Messchendorp, Paul J. M. van der Boog, et al. (+3)
3 [GO] 2022―Nov―20 How a Pandemic Simultaneously Strengthened Existing Fundamentals and Drove New Innovations in Clinical Pharmacology Shirley K. Seo, Piet H. van der Graaf
4 [GO] 2022―Sep―09 CYP450 3A4 /5 Containment During SARS-CoV -2 Infection Jean Terrier, Camille Lenoir, Caroline Samer
5 [GO] 2022―Sep―06 Response to “ CYP450 3A4 /5 Containment During SARS-CoV -2 Infection” Edouard Charles Le Carpentier, Emmanuel Canet, Damien Masson, Ronan Bellouard, Matthieu Grégoire
6 [GO] 2022―Aug―19 Assessing the Combined Public Health Impact of Pharmaceutical Interventions on Pandemic Transmission and Mortality: An Example in SARS CoV -2 Mohamed A. Kamal, Andreas Kuznik, Luyuan Qi, Witold Więcek, Mohamed Hussein, Hazem E. Hassan, et al. (+10)
7 [GO] 2022―Jul―07 Comparative pharmacokinetics of tixagevimab/cilgavimab ( AZD7442 ) administered intravenously versus intramuscularly in symptomatic SARS-CoV -2 infection Rachel A. Bender Ignacio, David A. Wohl, Rosalin Arends, Venkatesh Pilla Reddy, Ying Mu, Arzhang Cyrus Javan, et al. (+7)
8 [GO] 2022―May―14 Recommendations for the management of drug-drug interactions between the COVID-19 antiviral nirmatrelvir/ritonavir (Paxlovid ® ) and comedications Catia Marzolini, Daniel R. Kuritzkes, Fiona Marra, Alison Boyle, Sara Gibbons, Charles Flexner, et al. (+6)
9 [GO] 2022―May―05 Managing Potential Drug Interactions of Nirmatrelvir/Ritonavir in COVID-19 Patients: A Perspective from an Israeli Cross-Sector Collaboration Shiri Guy-Alfandary, Sasha Zhurat, Maya Berlin, Tal De Haan, Itai Gueta, Renata Shihmanter, et al. (+4)
10 [GO] 2022―Apr―07 Innovative Randomized Phase 1 Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID-19 Trial of Nirmatrelvir Ravi Shankar P. Singh, Sima S. Toussi, Frances Hackman, Phylinda L. Chan, Rohit Rao, Richard Allen, et al. (+10)
11 [GO] 2022―Apr―05 Physiologically Based Pharmacokinetic Modelling to Investigate Baricitinib and Tofacitinib Dosing Recommendations for COVID-19 in Geriatrics Ziteng Wang, Eric Chun Yong Chan
12 [GO] 2022―Mar―16 PBPK-led guidance for cystic fibrosis patients taking elexacaftor-tezacaftor-ivacaftor with nirmatrelvir-ritonavir for the treatment of COVID-19 Eunjin Hong, Lisa M. Almond, P.S. Chung, A. Peter Rao, Paul M. Beringer
13 [GO] 2022―Feb―16 ISPE-Endorsed Guidance in Using Electronic Health Records for Comparative Effectiveness Research in COVID-19: Opportunities and Trade-Offs Grammati Sarri, Dimitri Bennett, Thomas Debray, Anouk Deruaz-Luyet, Montse Soriano Gabarró, Joan A. Largent, et al. (+12)
14 [GO] 2022―Feb―10 Identification of risk factors for COVID-19 hospitalisation in patients with anti-rheumatic drugs: results from a multicentre nested case control study’ Merel A.A. Opdam, Sophie Benoy, Lise M. Verhoef, Sandra Van Bijnen, Femke Lamers-Karnebeek, R.A.M. Traksel, et al. (+3)
15 [GO] 2022―Feb―08 The Pandemic as a Catalyst for Disruptive Innovation in Clinical Pharmacology Kathleen M. Giacomini, Piet H. Graaf
16 [GO] 2022―Jan―28 The impact of Covid-19 on the initiation of clinical trials in Europe and the United States Florian Lasch, Eftychia-Eirini Psarelli, Ralf Herold, Andrea Mattsson, Lorenzo Guizzaro, Frank Pétavy, Anja Schiel
17 [GO] 2021―Dec―10 Exogenous sex hormones and sex hormone receptor modulators in COVID-19 ― rationale and clinical pharmacology considerations Peng Zou, Agiua Heath, Catherine Sewell, Yanhui Lu, Doanh Tran, Shirley K. Seo
18 [GO] 2021―Dec―04 Anticoagulant treatment regimens in patients with Covid-19: a meta-analysis Anselm Jorda, Jolanta M. Siller-Matula, Markus Zeitlinger, Bernd Jilma, Georg Gelbenegger
19 [GO] 2021―Dec―03 Features of inflammatory heart reactions following mRNA COVID-19 vaccination at a global level Laurent Chouchana, Alice Blet, Mohammad Al-Khalaf, Tahir S. Kafil, Girish Nair, James Robblee, et al. (+6)
20 [GO] 2021―Nov―22 Model Informed Drug Development Approaches to Assist New Drug Development in the COVID-19 Pandemic Ye Xiong, Jianghong Fan, Eliford Kitabi, Xinyuan Zhang, Youwei Bi, Manuela Grimstein, et al. (+6)
21 [GO] 2021―Nov―11 Science, Innovation, and Society in the Age of Pandemics: Reflections from the Inaugural Sir Alasdair Breckenridge Lecture Nokuthula Sikhethiwe Kitikiti, Uttara Soumyanarayanan, Silke Vogel, John C. W. Lim
22 [GO] 2021―Oct―26 An open label, adaptive, phase 1 trial of high-dose oral nitazoxanide in healthy volunteers: an antiviral candidate for SARS-CoV-2 Lauren E Walker, Richard FitzGerald, Geoffrey Saunders, Rebecca Lyon, Michael Fisher, Karen Martin, et al. (+27)
23 [GO] 2021―Sep―18 Scholarly Productivity in Clinical Pharmacology Amid Pandemic-Related Workforce Disruptions: Are Men and Women Affected Equally? Alethea B. Gerding, Sharon J. Swan, Kimberly A. Brayer, Susan M. Abdel-Rahman
24 [GO] 2021―Sep―13 Population pharmacokinetics and pharmacodynamics of the neutralizing antibodies bamlanivimab and etesevimab in patients with mild to moderate COVID-19 infection Emmanuel Chigutsa, Lisa O’Brien, Lisa Ferguson-Sells, Amanda Long, Jenny Chien
25 [GO] 2021―Sep―08 Physiologically based pharmacokinetic modelling to investigate the impact of the cytokine storm on CYP3A drug pharmacokinetics in COVID-19 patients Felix Stader, Manuel Battegay, Parham Sendi, Catia Marzolini
26 [GO] 2021―Sep―02 Impact of SARS-CoV-2 infection (COVID-19) on cytochromes P450 activity assessed by the Geneva cocktail Camille Lenoir, Jean Terrier, Yvonne Gloor, François Curtin, Victoria Rollason, Jules Alexandre Desmeules, et al. (+3)
27 [GO] 2021―Aug―29 First in Human Study of Bamlanivimab in a Randomized Trial of Hospitalized Patients with COVID-19 Peter Chen, Gourab Datta, Ying Grace Li, Jenny Chien, Karen Price, Emmanuel Chigutsa, et al. (+13)
28 [GO] 2021―Jul―27 DrugWAS: Drug-wide association studies for COVID-19 drug repurposing Cosmin A. Bejan, Katherine N. Cahill, Patrick J. Staso, Leena Choi, Josh F. Peterson, Elizabeth J. Phillips
29 [GO] 2021―Jul―09 US Taxpayers Heavily Funded the Discovery of COVID-19 Vaccines Hussain S. Lalani, Jerry Avorn, Aaron S. Kesselheim
30 [GO] 2021―Jun―17 Heterogeneity in COVID-19 Convalescent Plasma Clinical Trials Mirco Müller-Olling, Ute Vahlensieck, Anneliese Hilger
31 [GO] 2021―Jun―04 Association between FIASMAs and Reduced Risk of Intubation or Death in Individuals Hospitalized for Severe COVID-19: an observational multicenter study Nicolas Hoertel, Marina Sánchez-Rico, Erich Gulbins, Johannes Kornhuber, Alexander Carpinteiro, Eric J. Lenze, et al. (+71)
32 [GO] 2021―May―25 Japan’s special approval for emergency system during COVID-19 pandemic Hideki Maeda
33 [GO] 2021―Apr―22 Japan’s Drug Regulation During the COVID-19 Pandemic: Lessons From a Case Study of Favipiravir Munetaka Ueda, Tetsuya Tanimoto, Anju Murayama, Akihiko Ozaki, Masahiro Kami
34 [GO] 2021―Apr―01 Effect of corticosteroids on mortality in hospitalized COVID-19 patients not receiving invasive mechanical ventilation Federica Fusina, Filippo Albani, Enza Granato, Angelo Meloni, Renzo Rozzini, Tony Sabatini, et al. (+5)
35 [GO] 2021―Mar―14 Clinical Pharmacology-Informed Development of COVID-19 Therapeutics: Regulatory Experience Su-Young Choi, Vikram Arya, Kellie Reynolds
36 [GO] 2021―Mar―05 COVID-19 and the Emerging Regulatory Guidance for Ongoing Clinical Trials in the European Union Amos Jochanan de Jong, Yared Santa-Ana-Tellez, Ghislaine José Madeleine Wilhelmien van Thiel, Mira Gerta Petra Zuidgeest, Satu Johanna Siiskonen, Dinesh Mistry, et al. (+2)
37 [GO] 2021―Feb―28 Systematic review and patient-level meta-analysis of SARS-CoV-2 viral dynamics to model response to antiviral therapies Silke Gastine, Juanita Pang, Florencia A.T. Boshier, Simon J. Carter, Dagan O. Lonsdale, Mario Cortina-Borja, et al. (+4)
38 [GO] 2021―Feb―08 Neglecting plasma protein binding in COVID-19 patients leads to a wrong interpretation of lopinavir overexposure Francoise Stanke-Labesque, Didier Concordet, Zoubir Djerada, Stéphane Bouchet, Caroline Solas, Etienne Mériglier, et al. (+8)
39 [GO] 2021―Feb―05 Real-world evidence for assessing pharmaceutical treatments in the context of COVID-19 Jessica M. Franklin, Kueiyu Joshua Lin, Nicolle Gatto, Jeremy Rassen, Robert J. Glynn, Sebastian Schneeweiss
40 [GO] 2021―Jan―28 RAAS blockade and COVID-19: Mechanistic Modeling of mas and AT1 Receptor Occupancy as Indicators of Pro- and Anti-Inflammatory Balance Karen Melissa Hallow, Ishaan Dave
41 [GO] 2021―Jan―28 Collaborative platform trials to fight COVID-19: methodological and regulatory considerations for a better societal outcome Olivier Collignon, Carl-Fredrik Burman, Martin Posch, Anja Schiel
42 [GO] 2021―Jan―27 Physiologically-Based Pharmacokinetic Modeling of Remdesivir and its Metabolites to Support Dose Selection for the Treatment of Pediatric Patients with COVID-19 Justin D. Lutz, Anita Mathias, Polina German, Cheryl Pikora, Sunila Reddy, Brian J. Kirby
43 [GO] 2021―Jan―10 Nonspecific binding considerations in the rational design and development of small molecule COVID-19 therapeutics Tristan S. Maurer
44 [GO] 2021―Jan―10 Mechanistic modelling of SARS-CoV-2 and other infectious diseases and the effects of therapeutics Alan S. Perelson, Ruian Ke
45 [GO] 2020―Dec―17 Increasing Use of Compassionate Use/Managed Access Channels to Obtain Medicines for Use in COVID-19 Paul Aliu, Séverine Sarp, Paige Fitzsimmons
46 [GO] 2020―Nov―19 COVIDOSE: A phase 2 clinical trial of low-dose tocilizumab in the treatment of non-critical COVID-19 pneumonia Garth W. Strohbehn, Brian L. Heiss, Sherin J. Rouhani, Jonathan A. Trujillo, Jovian Yu, Alec J. Kacew, et al. (+17)
47 [GO] 2020―Oct―28 Towards consensus on correct interpretation of protein binding in plasma and other biological matrices for COVID-19 therapeutic development Marta Boffito, David J Back, Charles Flexner, Peter Sjö, Terrence F. Blaschke, Peter W. Horby, et al. (+4)
48 [GO] 2020―Sep―29 COVID-19: A Catalyst to Accelerate Global Regulatory Transformation Jerry Stewart, Peter Honig, Lina AlJuburi, Deborah Autor, Susan Berger, Patrick Brady, et al. (+14)
49 [GO] 2020―Sep―26 PharmGKB tutorial for pharmacogenomics of drugs potentially used in the context of COVID-19 Rachel Huddart, Michelle Whirl-Carrillo, Russ B. Altman, Teri E. Klein
50 [GO] 2020―Sep―21 Role of Drugs used for chronic disease management on Susceptibility and Severity of COVID-19: A Large Case-Control Study Huadong Yan, Ana M Valdes, Amrita Vijay, Shanbo Wang, Lili Liang, Shiqing Yang, et al. (+11)
51 [GO] 2020―Aug―27 Possible role of ABCB1 in lysosomal accumulation of azithromycin in COVID-19 therapy Jean-Michel Scherrmann
52 [GO] 2020―Aug―08 Physiologically-Based Pharmacokinetic Modeling to Predict the Clinical Efficacy of the Coadministration of Lopinavir and Ritonavir against SARS-CoV-2 Aarzoo Thakur, Shawn Pei Feng Tan, James Chun Yip Chan
53 [GO] 2020―Jul―20 Pharmacokinetics and Pharmacological Properties of Chloroquine and Hydroxychloroquine in the Context of COVID-19 Infection Melanie R. Nicol, Abhay Joshi, Matthew L. Rizk, Philip E. Sabato, Radojka M. Savic, David Wesche, et al. (+2)
54 [GO] 2020―Jun―26 QT interval prolongation under hydroxychloroquine/ azithromycin association for inpatients with SARS-CoV-2 lower respiratory tract infection Sok-Sithikun Bun, Philippe Taghji, Johan Courjon, Fabien Squara, Didier Scarlatti, Guillaume Theodore, et al. (+10)
55 [GO] 2020―Jun―04 Pandemic Best Regulatory Practices: An Urgent Need in the Covid-19 Pandemic Murray M Lumpkin, John CW Lim
56 [GO] 2020―Jun―03 Applied Clinical Pharmacology in a Crisis - Interleukin-6 Axis Blockade and COVID-19 Garth W. Strohbehn, Pankti D. Reid, Mark J. Ratain
57 [GO] 2020―Jun―02 Oncology Treatment in the Era of COVID-19: We Cannot Afford to Hit the Pause Button Sarah A. Holstein, Julie M. Vose
58 [GO] 2020―May―23 A Real-World Evidence Framework for Optimising Dosing in All Patients with COVID-19 Richard W Peck, Daniel Weiner, Jack Cook, J Robert Powell
59 [GO] 2020―May―21 Management of osteoarthritis during COVID-19 pandemic Enrico Ragni, Laura Mangiavini, Marco Viganò, Anna Teresa Brini, Giuseppe Michele Peretti, Giuseppe Banfi, Laura de Girolamo
60 [GO] 2020―May―14 Clinical trials for Covid-19: can we better use the short window of opportunity? Hans-Georg Eichler, Marco Cavaleri, Harald Enzmann, Francesca Scotti, Bruno Sepodes, Fergus Sweeney, et al. (+2)
61 [GO] 2020―May―07 The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19 Virginia D. Schmith, Jie (Jessie) Zhou, Lauren RL Lohmer
62 [GO] 2020―May―01 Challenges in Drug Development Posed by the COVID-19 Pandemic: An Opportunity for Clinical Pharmacology Karthik Venkatakrishnan, Oezkan Yalkinoglu, Jennifer Q. Dong, Lisa J. Benincosa
63 [GO] 2020―Apr―30 COVID-19: a defining moment for clinical pharmacology? Piet H. van, Kathleen M. Giacomini
64 [GO] 2020―Apr―30 Dose rationale for favipiravir use in patients infected with SARS-CoV-2 Philippine Eloy, Caroline Solas, Franck Touret, France Mentré, Denis Malvy, Xavier de Lamballerie, Jérémie Guedj
65 [GO] 2020―Apr―30 Response to "Dose rationale for favipiravir use in patients infected with SARS-CoV-2" Yin-Xiao Du, Xiao-Ping Chen
66 [GO] 2020―Apr―29 Quantitative clinical pharmacology input to SARS-CoV-2 therapeutics should be based on robust data Joseph Standing
67 [GO] 2020―Apr―29 Response to “Quantitative clinical pharmacology input to SARS-CoV-2 therapeutics should be based on robust data” Maria Garcia-Cremades, Belen P. Solans, Emma Hughes, Jacqueline P. Ernest, Erika Wallender, Radojka M Savic
68 [GO] 2020―Apr―28 Finding the dose for hydroxychloroquine prophylaxis for COVID-19; the desperate search for effectiveness Mahmoud Al-Kofahi, Pamala Jacobson, David R Boulware, Arthur Matas, Raja Kandaswamy, Mutaz M Jaber, et al. (+3)
69 [GO] 2020―Apr―23 Incidence of Adverse Drug Reactions in COVID-19 patients in China: an active monitoring study by Hospital Pharmacovigilance System Ji Sun, Xuanyu Deng, Xiaoping Chen, Juanjuan Huang, Siqiong Huang, Yanfei Li, et al. (+3)
70 [GO] 2020―Apr―22 Chloroquine dosing recommendations for pediatric COVID-19 supported by modeling and simulation Laurens F.M. Verscheijden, Tjitske M. van der Zanden, Lianne P.M. van Bussel, Marika de Hoop-Sommen, Frans G.M. Russel, Trevor N. Johnson, Saskia N. de Wildt
71 [GO] 2020―Apr―22 Risks of ACE inhibitor and ARB usage in COVID-19: evaluating the evidence Krishna Sriram, Paul A. Insel
72 [GO] 2020―Apr―20 Off-Label Therapies for COVID-19-Are We All In This Together? Jonathan D. Alpern, Elie Gertner
73 [GO] 2020―Apr―17 Clinical Pharmacology Perspectives on the Antiviral Activity of Azithromycin and Use in COVID-19 Bharat Damle, Manoli Vourvahis, Erjian Wang, Joanne Leaney, Brian Corrigan
74 [GO] 2020―Apr―14 Optimizing hydroxychloroquine dosing for patients with COVID-19: An integrative modeling approach for effective drug repurposing Maria Garcia-Cremades, Belen P. Solans, Emma Hughes, Jacqueline P. Ernest, Erika Wallender, Francesca Aweeka, et al. (+2)
75 [GO] 2020―Apr―04 Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection Yin-Xiao Du, Xiao-Ping Chen
 [1] 

75 Results       Page 1


[de][en]

Last change 2022―Feb―03 17:06:14 UTC

© Daten-Quadrat 2022       Done in 0.005 sec